Precipio rises on commercial launch of COVID-19 antibody test

Precipio

30/07/2020 16:20

** Diagnostics company's shares  PRPO.O  rise 29.27% to
$1.59
    ** Company says commercially launching its COVID-19 antibody
test that will be distributed by ADS Biotec  urn:newsml:reuters.com:*:nGNX7Lr8Mb
    ** PRPO expects to first roll out a laboratory-run test in
August
    ** Following further U.S. FDA approval, test to be available
at physician offices as a point-of-care test and at retail
channels for at-home use, says company
    ** Precipio's antibody test, which detects the body's immune
response to infection caused by coronavirus, recently received
FDA's emergency use authorization
    ** Company's shares down ~22% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))